How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

331 results for

Pemphigus Foliaceus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Pemphigus Foliaceus (PubMed)

Pemphigus Foliaceus 19992758 2010 06 24 2010 06 24 0035-9157 37 3 1944 Jan Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Pemphigus Foliaceus. 73-4 Wigley J E JE eng Journal Article England Proc R Soc Med 7505890 0035-9157 2009 12 9 6 0 1944 1 1 0 0 1944 1 1 0 1 ppublish 19992758 PMC2180884

Full Text available with Trip Pro

1944 Proceedings of the Royal Society of Medicine

122. Pemphigus Foliaceus Complicated by Peripheral Vascular Disease (PubMed)

Pemphigus Foliaceus Complicated by Peripheral Vascular Disease 19994045 2010 06 25 2018 11 13 0035-9157 53 4 1960 Apr Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Pemphigus Foliaceus Complicated by Peripheral Vascular Disease. 298 Garretts M M eng Journal Article England Proc R Soc Med 7505890 0035-9157 2009 12 9 6 0 1960 4 1 0 0 1960 4 1 0 1 ppublish 19994045 PMC1871202 Br J Dermatol. 1959 Jun;71(6):223-5 13662523 Am J Med. 1950 Dec;9(6):752-6 14789795

Full Text available with Trip Pro

1960 Proceedings of the Royal Society of Medicine

123. Generalized Vaccinia in Patients with Pemphigus Foliaceus (PubMed)

Generalized Vaccinia in Patients with Pemphigus Foliaceus 13991124 1998 11 01 2018 12 01 0032-5473 39 1963 Feb Postgraduate medical journal Postgrad Med J Generalized vaccinia in patients with pemphigus foliaceus. 86-90 de SALLES-GOMES L L RABELLO S I SI MAGALDI-JORDAO F B FB PEDERNEIRAS C A CA AMOROSINO A A ANGULO J J JJ eng Journal Article England Postgrad Med J 0234135 0032-5473 OM Humans Pemphigus Vaccinia PEMPHIGUS VACCINIA 1963 2 1 1963 2 1 0 1 1963 2 1 0 0 ppublish 13991124 PMC2482011 Br

Full Text available with Trip Pro

1963 Postgraduate medical journal

124. A Case of Pemphigus Foliaceus (PubMed)

A Case of Pemphigus Foliaceus 20754866 2011 03 29 2011 03 29 0007-1447 1 1745 1894 Jun 09 British medical journal Br Med J A Case of Pemphigus Foliaceus. 1237-8 Cuthbert C F CF eng Journal Article England Br Med J 0372673 0007-1447 2010 8 27 6 0 1894 6 9 0 0 1894 6 9 0 1 ppublish 20754866 PMC2405252

Full Text available with Trip Pro

1894 British medical journal

125. Pemphigus Foliaceus of Sixteen Years' Duration (PubMed)

Pemphigus Foliaceus of Sixteen Years' Duration 19974977 2010 06 24 2010 06 24 0035-9157 4 Dermatol Sect 1911 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Pemphigus Foliaceus of Sixteen Years' Duration. 15-7 Adamson H G HG eng Journal Article England Proc R Soc Med 7505890 0035-9157 2009 12 9 6 0 1911 1 1 0 0 1911 1 1 0 1 ppublish 19974977 PMC2004924

Full Text available with Trip Pro

1911 Proceedings of the Royal Society of Medicine

126. Pemphigus Foliaceus (PubMed)

Pemphigus Foliaceus 19982227 2010 06 24 2010 06 24 0035-9157 15 Dermatol Sect 1922 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Pemphigus Foliaceus. 20 Gray A M AM eng Journal Article England Proc R Soc Med 7505890 0035-9157 2009 12 9 6 0 1922 1 1 0 0 1922 1 1 0 1 ppublish 19982227 PMC2103260

Full Text available with Trip Pro

1922 Proceedings of the Royal Society of Medicine

127. Pemphigus Foliaceus (PubMed)

Pemphigus Foliaceus 19991532 2010 06 24 2010 06 24 0035-9157 31 8 1938 Jun Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Pemphigus Foliaceus. 871 Gray A M AM eng Journal Article England Proc R Soc Med 7505890 0035-9157 2009 12 9 6 0 1938 6 1 0 0 1938 6 1 0 1 ppublish 19991532 PMC2076800

Full Text available with Trip Pro

1938 Proceedings of the Royal Society of Medicine

128. Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid. (PubMed)

define cut-off values for Dsg1, Dsg3, and BP180, we evaluated 47 serum samples from patients with pemphigus foliaceus (PF), 59 from those with pemphigus vulgaris (PV), 52 from those with bullous pemphigoid (BP), and 995 from healthy individuals. We also evaluated any fluctuations in CLEIA titers according to disease activity during the clinical course of 10 cases each of PF, PV, and BP. We used clinical symptom scores, the pemphigus disease area index (PDAI) and the bullous pemphigoid disease area (...) Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid. A novel chemiluminescent enzyme immunoassay (CLEIA) was recently developed to quantify autoantibodies specific for desmogleins (Dsgs) and BP180, the target antigens of pemphigus and pemphigoid. This assay is automated and highly accurate and efficient.To validate the use of the CLEIA for detection of autoantibodies during the clinical courses of patients with pemphigus and pemphigoid.To

2016 Journal of dermatological science

129. Pemphigus (PubMed)

Pemphigus Pemphigus is a group of IgG-mediated autoimmune diseases of stratified squamous epithelia, such as the skin and oral mucosa, in which acantholysis (the loss of cell adhesion) causes blisters and erosions. Pemphigus has three major subtypes: pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus. IgG autoantibodies are characteristically raised against desmoglein 1 and desmoglein 3, which are cell-cell adhesion molecules found in desmosomes. The sites of blister formation (...) can be physiologically explained by the anti-desmoglein autoantibody profile and tissue-specific expression pattern of desmoglein isoforms. The pathophysiological roles of T cells and B cells have been characterized in mouse models of pemphigus and patients, revealing insights into the mechanisms of autoimmunity. Diagnosis is based on clinical manifestations and confirmed with histological and immunochemical testing. The current first-line treatment is systemic corticosteroids and adjuvant

Full Text available with Trip Pro

2017 Nature reviews. Disease primers

130. Pemphigus Foliaceus

Pemphigus Foliaceus Pemphigus Foliaceus - Dermatologic Disorders - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge Diagnostic Tests (...) University Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Pemphigus foliaceus is an autoimmune blistering disorder in which splits in the superficial epidermis result in cutaneous erosions. Bullae are elevated, fluid-filled blisters ≥ 10 mm in diameter. Pemphigus foliaceus usually occurs in middle-aged patients, affecting men and women in equal numbers. An endemic form of pemphigus foliaceus, fogo selvagem, occurs in younger adults and children, particularly in South

2013 Merck Manual (19th Edition)

131. E-cadherin autoantibody profile in Pemphigus Vulgaris (E-cadherin autoantibody profile in Pemphigus Vulgaris patients). (PubMed)

E-cadherin autoantibody profile in Pemphigus Vulgaris (E-cadherin autoantibody profile in Pemphigus Vulgaris patients). Pemphigus vulgaris (PV) is an autoimmune skin blistering disease. The main targets of autoantibodies are the desmosomal proteins desmoglein (Dsg)3 and Dsg1. Anti-E-cadherin antibody is the second most frequent antibody found in pemphigus foliaceus (fogo selvagem), but the frequency in PV is unknown.To determine the anti-E-cadherin antibody profile in the two major subtypes

Full Text available with Trip Pro

2013 British Journal of Dermatology

132. Data on HLA class I/II profile in Brazilian pemphigus patients (PubMed)

Data on HLA class I/II profile in Brazilian pemphigus patients Pemphigus are blistering autoimmune diseases related with genetic and environmental factors. Here we describe HLA genotyping in pemphigus patients. First, we review the HLA class I/II data on pemphigus reported in Brazilian samples and then present the HLA class I (-A, -B, -C) and class II (-DRB1, -DQA1, -DQB1) alleles related to susceptibility/resistance to pemphigus by comparing 86 patients with pemphigus foliaceus, 83 patients (...) with pemphigus vulgaris, and 1592 controls from the northeastern region of the state of São Paulo, Southeastern Brazil. The data presented here are related to the manuscript "Differential HLA class I and class II associations in Pemphigus Foliaceus and Pemphigus Vulgaris patients from a prevalent Southeastern Brazilian region" Brochado et al. (2016) [1].

Full Text available with Trip Pro

2016 Data in brief

133. Immune response in pemphigus and beyond: progresses and emerging concepts. (PubMed)

Immune response in pemphigus and beyond: progresses and emerging concepts. Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are two severe autoimmune bullous diseases of the mucosae and/or skin associated with autoantibodies directed against desmoglein (Dsg) 3 and/or Dsg1. These two desmosomal cadherins, typifying stratified epithelia, are components of cell adhesion complexes called desmosomes and represent extra-desmosomal adhesion receptors. We herein review the advances in our (...) understanding of the immune response underlying pemphigus, including human leucocyte antigen (HLA) class II-associated genetic susceptibility, characteristics of pathogenic anti-Dsg antibodies, antigenic mapping studies as well as findings about Dsg-specific B and T cells. The pathogenicity of anti-Dsg autoantibodies has been convincingly demonstrated. Disease activity and clinical phenotype correlate with anti-Dsg antibody titers and profile while passive transfer of anti-Dsg IgG from pemphigus patients

2015 Seminars in immunopathology

134. Usefulness of specific anti-desmoglein 1 and 3 enzyme-linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity. (PubMed)

vulgaris (PV) and nine with pemphigus foliaceus (PF) during the course of the disease. In each sample, we measured anti-Dsg1 and anti-Dsg3 antibodies by ELISA. A receiver operating characteristics (ROC) curve was calculated to determine a cutoff value for anti-Dsg1 and anti-Dsg3 antibodies with optimal sensitivity and specificity. In 263 samples, we compared the ROC curves of anti-Dsg1 and anti-Dsg3 antibodies with the ROC curves of the IIF results.Activity of pemphigus was associated with a wide range (...) Usefulness of specific anti-desmoglein 1 and 3 enzyme-linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity. The objective was to assess the relationship between enzyme-linked immunoassay (ELISA) values of desmoglein (Dsg) 1 and Dsg3 antibodies and indirect immunofluorescence (IIF) values of anti-epithelial antibodies with disease activity in patients with pemphigus.In a retrospective study, we analyzed 353 serum samples taken from 35 patients with pemphigus

2015 International Journal of Dermatology

135. Wound Dressings for Pemphigus and Pemphigoid

Inclusion Criteria: Diagnosis of pemphigus vulgaris, pemphigus foliaceus , pemphigus vegetans, paraneoplastic pemphigus or bullous pemphigoid At least four areas of active disease in the trunk or limbs of 8 x 8 cm characterized by denudation, ulceration, scabs or blisters. Capable of being evaluated weekly either as outpatient or hospitalized Actively treated with immunosuppressive or immunomodulatory drugs for pemphigus or pemphigoid control Willing to sign an informed consent Exclusion Criteria (...) Wound Dressings for Pemphigus and Pemphigoid Wound Dressings for Pemphigus and Pemphigoid - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Wound Dressings for Pemphigus and Pemphigoid The safety

2015 Clinical Trials

136. A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris

study participation Able to comply with the study protocol, in the investigator's judgment Exclusion Criteria: Diagnosis of pemphigus foliaceus or evidence of paraneoplastic pemphigus or other non-PV autoimmune blistering disease History of a severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies, or known hypersensitivity to any component of rituximab Known hypersensitivity or contraindication to MMF, mycophenolic acid, polysorbate, or oral corticosteroids Lack (...) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2015 Clinical Trials

137. Durable remission of pemphigus with a fixed-dose rituximab protocol. (PubMed)

intravenously if clinically warranted at 6-month intervals or repeated full dosing).A retrospective cohort study was conducted using records from a tertiary referral center for autoimmune bullous disorders. Participants included 92 patients (pemphigus vulgaris, 84 [91%], and pemphigus foliaceus, 8 [9%]) who received rituximab treatment between May 1, 2006, and August 30, 2012.The primary outcomes were time to relapse and achievement of a complete response with or without treatment at the end (...) Durable remission of pemphigus with a fixed-dose rituximab protocol. Rituximab induces B-lymphocyte apoptosis by targeting CD20 antigen and has shown efficacy in antibody-mediated autoimmune disease. Rituximab is increasingly being acknowledged as an effective and safe treatment option for pemphigus.To assess the clinical response of patients with pemphigus to rituximab using a modified fixed-dose rheumatoid arthritis protocol (1 g intravenously on days 1 and 15, followed by 500 mg

Full Text available with Trip Pro

2014 JAMA dermatology (Chicago, Ill.)

138. Clinical and immunological profiles in 17 Japanese patients with drug-induced pemphigus studied at Kurume University. (PubMed)

and 2012. Complicated diseases, clinical and histopathological manifestations, responsible drugs and findings in immunofluorescence, enzyme-linked immunosorbent assays (ELISAs), immunoblotting (IB) and prognosis were analysed.Eight of the 17 patients with DIP showed pemphigus foliaceus-like appearance, three showed pemphigus herpetiformis-like appearance, and six showed atypical bullous lesions. Responsible drugs were thiol-containing drugs in 16 patients (bucillamine in nine cases, d-penicillamine (...) -kDa periplakin. Four cases showed anti-Dsg3 antibodies without mucosal lesions. While 11 cases recovered after discontinuation of the causative drugs, six patients had a very protracted or intractable disease course, and might develop true pemphigus.The present study indicated that the majority of the patients with DIP studied showed a pemphigus foliaceus-type phenotype with anti-Dsg1 autoantibodies, caused by thiol-containing drugs.© 2014 British Association of Dermatologists.

2014 British Journal of Dermatology

139. Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. (PubMed)

Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. Pemphigus foliaceus (PF) and pemphigus vulgaris (PV) are life-threatening autoimmune blistering skin diseases. They are characterized by circulating autoantibodies which bind to the ectodomains of desmoglein (Dsg) 1 and Dsg3. These antibodies induce acantholysis in skin and mucous membranes. In severe cases of pemphigus, immunoadsorption is applied to remove total IgG from patient (...) were mainly conformation-dependent. However, adsorption of pemphigus foliaceus IgG using this protein coupled to a Sepharose matrix did not completely remove pathogenicity from the sera, as proven by a keratinocyte dissociation assay. In contrast, full-length Dsg1 and Dsg3 ectodomains were able to specifically adsorb anti-Dsg antibodies and to efficiently eliminate pathogenicity. Therefore, the complete and correctly folded ectodomains of both desmogleins are required for therapeutic

2014 Experimental Dermatology

140. Cutaneous pemphigus vulgaris with absence of desmoglein 1 autoantibodies. An example of the extended desmoglein compensation theory. (PubMed)

Cutaneous pemphigus vulgaris with absence of desmoglein 1 autoantibodies. An example of the extended desmoglein compensation theory. A 79 year-old male patient presented clinically as a typical case of pemphigus foliaceus. He displayed a seborrhoeic pattern of crusting and erosions with an absence of oral involvement. Surprisingly, a biopsy showed suprabasilar acantholysis and direct immunofluorescence consistent with pemphigus vulgaris. Indirect pemphigus antibodies were positive (...) for desmoglein 3 (DSG-3) but negative for DSG-1 antibodies. Most cases of cutaneous pemphigus are reported to have both DSG-1 and DSG-3 antibodies. A rare cutaneous subtype of pemphigus vulgaris is reported in the literature that may present clinically as seen in our patient. Our patient is clinically similar to these previous reported cases but with a negative DSG-1 antibody titre. The extended DSG compensation theory explains the differences of clinical expression in pemphigus based on the variable

2014 Australasian Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>